This leads to better adherence to treatment plans
RAW 264.7 cells were cultured with 100 ng/mL of LPS at 10 ascending doses (6.6, 13.3, 26.6, 53.1, 106.3, 212.5, 425, 850 nM, 1.7 and 3.4 M) of liraglutide for 24 h to determine the IC 50 of the pro-inflammatory mediators NO, PGE 2 , and IL-6 (Fig
Human validation of genes associated with a murine atherosclerotic phenotype
At Boca Medical Care, patient safety is our top priority
Common (typically mild and transient): Increased appetite (moderate, less than GHRP-6) Flushing and warmth at the injection site or face Transient drowsiness or sleepiness, particularly with evening doses Mild water retention and peripheral edema Increased gastrointestinal motility Less Common: Elevations in cortisol and ACTH (moderate, comparable to hCRH) Mild prolactin elevation (less than TRH-induced levels) Numbness or tingling in extremities Joint stiffness Lightheadedness post-injection Rare or Theoretical Concerns: Impaired glucose metabolism and elevated blood glucose with prolonged use Potential tachyphylaxis (reduced response) with continuous daily dosing Theoretical promotion of existing malignancies through elevated GH/IGF-1 (applies to all GH-elevating compounds) Side effect incidence tends to be lower than with exogenous hGH because GHRP-2 stimulates endogenous GH synthesis within physiological regulatory limits